Auricularia (Wood Ear / Jelly Ear Fungi): A Comprehensive Reference
1. Identity and Taxonomy
1.1 The Genus
Auricularia is a genus of fungi in the family Auriculariaceae.
Basidiocarps (fruit bodies) are typically gelatinous and ear-shaped, with a slightly downy to conspicuously hirsute upper surface and an undersurface that is smooth, wrinkled, or veined.
All species grow on wood.
The genus was first introduced in 1780 by French mycologist Pierre Bulliard for a range of different fungi producing fruit bodies with an ear-like shape.
The name Auricularia is derived from the Latin word auricula, meaning "ear."
1.2 Principal Species and Nomenclature
Three primary species are of pharmacological and commercial importance:
- Auricularia auricula-judae (Bull.) Quél. — Commonly known as wood ear, jelly ear, or historically as Jew's ear, it is a species of fungus in the order Auriculariales.
The species was first described as Tremella auricula by Carl Linnaeus in his 1753 Species Plantarum and later (1789) redescribed by Jean Baptiste François Pierre Bulliard as Tremella auricula-judae.
After several changes of genus, this fungus was transferred into its present genus in 1897 by Austrian botanist-mycologist Richard Wettstein.
Molecular research, based on cladistic analysis of DNA sequences, has shown that Auricularia auricula-judae as previously understood comprises at least seven different species worldwide; since it was originally described from Europe, the name is now restricted to the European species.
- Auricularia heimuer F. Wu, B.K. Cui & Y.C. Dai — Also known as heimuer (Chinese: 黑木耳; pinyin: hēimù'ěr) or black wood ear.
The commercially cultivated Chinese and East Asian species, still frequently marketed and described as A. auricula-judae or A. auricula, is Auricularia heimuer (black wood ear).
It is commercially cultivated for food in China at a value exceeding $4 billion (USD) per year.
- Auricularia cornea Ehrenb. (syn. A. polytricha) — Also called A. polytricha, it is another commercially cultivated wood ear known as cloud ear.
These species, Auricularia auricula and Auricularia polytricha, are occasionally misidentified and used interchangeably.
Among the many synonyms that this ubiquitous woodland fungus has gathered are Tremella auricula L., Peziza auricula-judae (Bull.) Bolton, Tremella auricula-judae Bull., Exidia auricula-judae (Bull.) Fr., and Hirneola auricula-judae (Bull.) Berk.
1.3 Macroscopic Description and Natural Habitat
Basidiocarps (fruit bodies) are brown, gelatinous, and have a noticeably ear-like shape.
The texture is tough, gelatinous, and elastic when fresh, but when dried it is hard and brittle.
The fungus can be found throughout the year in Europe, where it normally grows on wood of broadleaf trees and shrubs.
The mushrooms grow in groupings, predominantly on elder trees, but have also been found on dead and living trees such as ash, spindle, and beech.
It is found in Europe, Asia, North Africa, and North America.
1.4 Commercial Production and Common Preparations
At least three species are commercially cultivated for food on a large scale in China and East Asia.
According to a 2010 publication, the annual production of Auricularia species worldwide is the fourth highest among all industrially cultivated culinary and medicinal mushrooms; the estimated annual output in China in 2013 was 4.75 billion kg in fresh weight, with a value of about four billion US dollars.
Wood ear mushrooms are also cultivated around the world on bags of sawdust and are dried and exported for commercial use.
Common forms and preparations include:
- Dried whole fruiting bodies — the dominant commercial form globally, rehydrated before culinary or medicinal use.
- Powder and capsules — ground dried fruiting body, used in dietary supplements.
- Water or hot-water extracts — used in both traditional decoctions (soups, teas) and modern standardized liquid or encapsulated extracts.
- Purified polysaccharide preparations — investigated in pharmacological research and, in some markets, formulated as functional food ingredients.
- Ethanol extracts — used in research and some supplement formulations to concentrate polyphenolic and other non-polysaccharide fractions.
2. Traditional and Historical Use
2.1 Traditional Chinese Medicine (TCM)
In China, the use of an Auricularia species, probably A. heimuer, as a food and a medicine was recorded in the 3rd-century Chinese medicinal book Shennong Ben Cao Jing. Species were being cultivated in China as early as the Tang dynasty (618–907 CE).
Li Shizhen, in his Pen Tsao Kang Mu, quotes Tang Ying-chuan from that period as saying "put the steamed bran on logs, cover with straw, Wood Ear will grow."
This mushroom has been used in traditional Chinese medicine (TCM) since at least 200 CE, with documented references in the classic herbal compendium Shennong Bencao Jing. Its jelly-like texture and alleged ability to "moisten dryness" made it a go-to remedy in treating respiratory ailments, especially persistent dry coughs and throat irritations.
In Buddhist vegetarian cuisine, it provided a morally acceptable meat substitute because of its chewy, flesh-like bite. Traditional medicine practitioners compiled it into the materia medica, along with other fungi believed to nourish "Yin" and moist tissue.
Dietary intake of A. auricula was recorded in the Shen Nong's Herbal Classic as able to alleviate hypertension, vascular sclerosis, and malignant dysentery.
A soup containing the species is used medicinally for dealing with colds and fevers in the belief that it reduces the heat of the body.
Revered as a blood tonic and for its cooling qualities, it has especially been used to support cardiovascular health and prevent excessive clotting. Traditional practitioners often brew it into teas or soups to nourish the lungs, increase bodily moisture, and help with dry skin or throat irritation. It is also thought to combat internal dryness and support digestion.
In China, it is known as hei mu er (black wood ear), and has traditionally been prized during the Lunar New Year for bringing good health and longevity.
Culturally, it was considered food for the elite and was used in ceremonial dishes, symbolizing delicacy and prosperity.
2.2 European Folk Medicine
Auricularia auricula-judae was used in folk medicine as recently as the 19th century for complaints including sore throats, sore eyes, and jaundice, and as an astringent.
Its use in European ethnomedicine has a very long tradition. It has been sold in pharmacies as Fungus Sambuci, and it is used as a gargle for the treatment of sore throats, as well as sore eyes and jaundice; it is also used as an astringent.
Carolus Clusius, writing in 1601, also said that the species could be gargled to cure a sore throat, and John Parkinson, writing in 1640, reported that boiling in milk or steeping in vinegar was "the only use they are put unto that I know."
Writing in 1694, the herbalist John Pechey described A. auricula-judae by saying "It grows to the Trunk of the Elder-Tree. Being dried it will keep a good year. Boyl'd in Milk, or infus'd in Vinegar, 'tis good to gargle the Mouth or Throat in Quinsies, and other inflammations of the Mouth and Throat. And being infus'd in some proper Water, it is good in Diseases of the Eyes."
The species also saw use as an astringent due to its ability to absorb water. There are recorded medicinal usages from Scotland, where it was again used as a gargle for sore throats, and from Ireland, where, in an attempt to cure jaundice, it was boiled in milk.
The medicinal use of A. auricula-judae continued until at least 1860, when it was still sold at Covent Garden.
Medicinal use in Indonesia was also recorded in the 1930s, and was more recently reported in modern-day Ghana.
2.3 Other Traditional Uses
Auricularia polytricha is a mushroom that is used traditionally for treating asthma, rheumatism, tumors, cough, fever, and epilepsy, and for its antimicrobial effect.
In Chinese and West African folk medicines, the fungus is reported to be used as an astringent for treating sore throats, jaundice, and sore eyes. The topical application of fresh Auricularia auricula-judae is also indicated for treating tonsillitis, ophthalmia, laryngocele, and staphylococcus infections.
It is also used in Ghana as a blood tonic.
3. Key Constituents and Active Compounds
3.1 Polysaccharides (AAPs)
The fruiting body of Auricularia auricula is widely used as food and medicine in East Asia. The polysaccharides extracted from Auricularia auricula (AAPs) are the key bioactive components of the fungus.
AAPs are composed of a D-glucose residue backbone and various β-1,3-branched residue chains, such as glucose, mannose, and xylose.
The fruit of Auricularia auricular-judae is rich in hetero-polysaccharides that consist of a D-glucose residue backbone with various chains of β-1,3-branch residues, such as mannose, glucose, xylose, and glucuronic acid.
An acidic polysaccharide with anticoagulant activity was isolated from the edible mushroom Auricularia auricula using water, alkali, or acid extracts; the alkali extract showed the highest anticoagulant activity and was further purified. The specific anticoagulant activity of the purified polysaccharide was 2 IU/mg and its average mass was approximately 160 kDa. The polysaccharide contains mainly mannose, glucose, glucuronic acid, and xylose but no sulfate esters.
One characterized fraction, AAP-b2, contained 87.01 ± 1.58% carbohydrate, 1.73 ± 0.07% protein, and 18.77 ± 1.25% uronic acid, and was mainly composed of four monosaccharides: mannose, glucuronic acid, glucose, and xylose, with a molar ratio of 89.25:30.50:4.25:1.00.
The application of AAP faces challenges due to its high molecular mass and complex chemical structure. The intricate structure of AAP, characterized by diverse branching and high molecular mass, enhances biological activities but also makes the compounds difficult to study and utilize effectively.
3.2 Dietary Fiber and Beta-Glucans
Auricularia is a rich source of dietary fiber. Most of the carbohydrates in Auricularia have been reported to be indigestible polysaccharides, such as β-glucans and mannans.
Auricularia species have been shown to contain higher fiber content than other commercially available mushrooms such as Agaricus bisporus and Ganoderma lucidum.
Auricularia auricula-judae stands out among edible mushrooms; it contains more dietary fiber than any other edible mushroom — up to 70–80% of its dry weight.
3.3 Melanin
The dark color of Auricularia fruiting bodies is attributable to fungal melanin. Melanin extracted from Auricularia shows promise in antioxidant and antibacterial formulations. Research published in the journal Food Science and Biotechnology has documented the physicochemical properties and antioxidant activities of melanin fractions from Auricularia auricula fruiting bodies.
3.4 Polyphenolic Compounds
The cholesterol-lowering properties of Auricularia auricula are commonly attributed to the presence of polysaccharides based on previous research, but the ethanol extract of A. auricula (AAE) contained more than 16% (g/g) polyphenolic compounds, excluding other interfering factors such as polysaccharides, water-soluble fibre, and protein.
These results indicated that A. auricula functional components which prevented hypercholesterolemia contained polyphenolic compounds, in addition to polysaccharides.
3.5 Minerals and Other Nutrients
A. auricula is a rich source of protein, polysaccharides, vitamins, minerals (especially calcium, iron, and magnesium), and other nutrients.
Auricularia species have very low soluble sugar content, which is reflected in their flavor, and have a low fat content.
4. Established and Proposed Mechanisms of Action
4.1 Anticoagulant and Antithrombotic Mechanisms
The anticoagulant activity of the isolated polysaccharide is due to catalysis of thrombin inhibition by antithrombin, but not by heparin cofactor II. Inhibition of Factor Xa by antithrombin was not catalyzed by the polysaccharide. The glucuronic acid residues were essential for the anticoagulant action, since the activity disappeared after reduction of its carboxyl groups.
The antithrombotic activity of the purified polysaccharide fraction AAP-b2 was found to be related to the inhibition of platelet activation by regulation of endothelial nitric oxide synthases (eNOs), endothelin-1 (ET-1), prostacyclin (PGI2), and thromboxane B2 (TXB2), along with the enhancement of anticoagulant activity by affecting antithrombin III (AT-III) and protein C (PC) pathways.
The anticoagulant and antithrombotic activities of these polysaccharides are closely related to the presence of uronic acid.
In ex vivo tests using rats orally fed with the polysaccharide, an inhibitory effect on platelet aggregation was observed comparable to that of aspirin, a well-known antiplatelet agent. The polysaccharides from these mushrooms may constitute a new source of compounds with action on coagulation, platelet aggregation, and, perhaps, on thrombosis.
4.2 Lipid-Lowering Mechanisms
Bile acid binding capacity has been proposed as one mechanism by which Auricularia polysaccharides may exert hypolipidemic effects, with improvement in bile acid binding indicating enhanced hypolipidemic activity.
In animal studies, dietary polysaccharide supplementation significantly regulated glucose and lipid metabolism, with measurable increases in total fecal bile acid excretion, suggesting a bile acid sequestration mechanism.
The HMG-CoA reductase pathway has also been implicated in the cholesterol-lowering effects of Auricularia auricula.
4.3 Immunomodulatory Mechanisms
AAPs regulate in vitro immune activity and exhibit antitumor and antioxidation biological activities.
The immuno-enhancing potential of polysaccharide from Auricularia auricula (AAP) has been an area of research interest; however, the immune-stimulatory activity and mechanisms of AAP in immunosuppressive conditions are still poorly understood.
AAP polysaccharides activate macrophages through TLR-4 and Dectin-1 receptors — immune cells that are among the first to respond to pathogens and tissue damage. The acidic character of these molecules, derived from uronic acids in the chain, produces a distinct interaction with pattern-recognition receptors — somewhat different from the neutral beta-glucans of shiitake or reishi.
4.4 Antioxidant Mechanisms
Ultrasonic treatment has been shown to reduce the molecular mass of AAP and significantly improve its antioxidant activities, with DPPH scavenging IC50 reduced from 3.58 mg/mL to 2.07 mg/mL and hydroxyl radical IC50 from 2.28 mg/mL to 1.77 mg/mL.
In animal models, AAP enhanced the activities of total superoxide dismutase (T-SOD), catalase (CAT), and glutathione peroxidase (GSH-Px), and reduced the content of malondialdehyde (MDA), thus alleviating oxidative stress injury.
4.5 Gut Microbiota Modulation
In previous studies, Auricularia auricula polysaccharides (AAP) have been found to improve type 2 diabetes mellitus, and research has sought to demonstrate that AAP achieves remission partly by altering the gut microbiota; in a type 2 diabetes mouse model, fasting blood glucose levels and oral glucose tolerance improved significantly after 5 weeks of AAP intervention.
AAP significantly inhibited inflammatory responses and balanced oxidative stress states in brain and colon tissues of hypercaloric diet-fed mice, while AAP dietary supplements remarkably reshaped gut bacterial composition; the abundance of Dubosiella, Bacteroides, and Parasutterella were significantly increased.
5. Scientific Evidence by Area of Use
5.1 Cardiovascular Health — Anticoagulant and Antiplatelet Activity
Preclinical evidence: An acidic polysaccharide with anticoagulant activity was isolated from Auricularia auricula using water, alkali, or acid extracts; the alkali extract showed the highest anticoagulant activity and was further purified using gel filtration chromatography. The study, published in Thrombosis Research (2003), represents a well-characterized preclinical investigation but involves in vitro and animal (rat oral feeding) methods only.
In ex vivo tests using rats orally fed with the polysaccharide, an inhibitory effect on platelet aggregation was observed, comparable to that seen with aspirin; the polysaccharides from these mushrooms may constitute a new source of compounds with action on coagulation, platelet aggregation, and, perhaps, on thrombosis.
A further PMC study identified a novel polysaccharide fraction (AAP-b2, 12.02 kDa) with carrageenan-induced thrombosis mouse model activity. The antithrombotic activity was found to be related to inhibition of platelet activation by regulation of eNOs, ET-1, PGI2, and TXB2, along with enhancement of anticoagulant activity by affecting AT-III and protein C pathways.
Evidence strength: Currently limited to in vitro and animal studies. No published randomized controlled trials (RCTs) in humans specifically evaluating anticoagulant or antiplatelet endpoints have been identified in the peer-reviewed literature. Translation to clinical practice requires further investigation.
5.2 Lipid Metabolism and Cardiovascular Risk
Preclinical evidence: An animal experiment administered ethanol extract of A. auricula (AAE) at 150 mg/kg/d body weight to ICR mice on a cholesterol-enriched diet for 8 weeks; AAE showed a remarkable hypocholesterolemic effect, improving antioxidant status, decreasing total cholesterol and atherosclerosis index, and increasing high-density lipoprotein cholesterol and fecal excretion of bile acids. No apparent effects on serum triglycerides or LDL-cholesterol were observed.
In a separate mouse model study using high-fat diet, dietary polysaccharide supplementation reduced body weight by 13.44%, liver index by 21.30%, epididymal fat index by 50.68%, fasting blood glucose by 14.27%, serum total cholesterol by 20.30%, and serum total triglycerides by 23.81%, while significantly increasing fecal bile acid output.
Clinical evidence: A patent document references clinical studies that showed the efficacy of an Auricularia auricula polysaccharide preparation (AP) in lowering serum lipids in humans; specifically, a multi-center study reportedly established beneficial effects in humans of AP on lowering total cholesterol and triglyceride levels, as well as increasing HDL-cholesterol levels. However, this evidence derives from a patent filing (US Patent 7,029,883) rather than an independently published peer-reviewed RCT.
A prospective Korean trial found that the intervention group consuming A. auricula-judae showed improved blood lipid levels, while the control group showed an increase in total cholesterol and LDL-cholesterol levels, with results consistent across previous studies.
This study evaluated functional foods containing Auricularia auricula-judae powder on gut health and clinical indicators in middle-aged and older adults; participants were randomly assigned to either the intervention group (n = 24) or control group (n = 26), and the intervention group consumed functional foods containing A. auricula-judae powder twice daily for 8 weeks. No statistically significant differences were observed in gut environmental parameters between the two groups.
Evidence strength: Predominantly animal/in vitro. The available human evidence is limited in volume, scale, and independent verification. Existing human data are promising but insufficient to draw firm clinical conclusions.
5.3 Blood Glucose Regulation and Metabolic Effects
Preclinical evidence: Auricularia auricula polysaccharides (AAP) have demonstrated several advantages including reducing sterols, antioxidant properties, lowering blood lipids, and regulating immune function.
In a mouse type 2 diabetes model induced by high-fat diet and streptozotocin, fasting blood glucose levels and oral glucose tolerance improved significantly after 5 weeks of AAP intervention.
A dose of AAP-M at 200 mg/kg/d displayed the best improvement effect in this model.
Further studies on ultrasound-modified AAP fragments showed that hypoglycemic effects were improved, with α-amylase and α-glucosidase inhibition rates increasing by 5.06% and 5.81%, respectively, compared to unmodified fractions.
Evidence strength: All published blood glucose evidence meeting peer-review standards is in animal or cell models. No sufficiently powered human RCTs for glycemic endpoints have been identified.
5.4 Immunomodulation
Preclinical evidence: A PMC study aimed to evaluate the immuno-enhancing effects of AAP and mine its possible mechanisms; polysaccharides were isolated and purified from A. auricula, and the immune-stimulatory activities of the first AAP fraction (AAP1) were evaluated in cyclophosphamide (CTX)-treated immunosuppressed mice.
AAP has been suggested to play important biological roles, such as hypoglycemic, hypolipidemic, antioxidant, antitumor, and antiviral activities.
Evidence strength: Immunomodulatory evidence is entirely preclinical (in vitro and animal models). Mechanistic data are preliminary. No clinical trials in humans have been identified for immunological outcomes specifically attributable to Auricularia.
5.5 Antitumor Activity
Preclinical evidence: One PMC study evaluated and compared the antitumor activity of different solvent fractions of the Auricularia auricula-judae 70% ethanol extract on P388D1 macrophage and sarcoma 180 cells; a dose-dependent antitumor activity of each solvent fraction (from 0.01 mg/ml to 0.3 mg/ml) was shown against both cell types, confirmed on MTT and SRB assays. The IC50 value of the dichloromethane fraction was 94.2 μg/ml against sarcoma 180 cells, lower than any other solvent fractions.
Chemically modified polysaccharides of mushrooms exhibited potent antitumor activity, while water-insoluble and alkali-soluble polysaccharides had little or no antitumor activity. The modified alkali-insoluble β-glucan of Auricularia auricula-judae showed potent antitumor activity.
It has been reported that polysaccharides from A. auricula show antioxidant, antitumor, and radioprotective activities.
Evidence strength: Antitumor evidence is entirely in vitro and in animal models. There are no human clinical trials evaluating antitumor effects of Auricularia preparations. These findings are hypothesis-generating only.
5.6 Anti-Inflammatory and Pulmonary Protection
Auricularia auricular-judae polysaccharide (AAP) has shown a variety of pharmacological properties. In one rat study, the role of AAP in acute lung injury (ALI) induced by lipopolysaccharide (LPS) was analyzed; adult Sprague-Dawley rats were randomly assigned into control, AAP, LPS, and LPS plus AAP groups. Rats were injected with LPS (10 mg/kg, intraperitoneally) to induce ALI, while rats in the LPS plus AAP group were treated with AAP for 7 days before induction.
Myeloperoxidase activity increased significantly following LPS administration; by contrast, pretreatment with AAP significantly decreased MPO activity and reduced neutrophil infiltration.
AAP was found to display strong antioxidant properties that may have beneficial effects on balancing pro- and anti-inflammatory mediators of the local wound environment. In previous studies, A. auricula mushroom extracts exhibited a variety of pharmacological properties such as antioxidant, blood lipid-lowering, anti-inflammation, antitumor, and anti-radiation activities; however, there was no direct evidence for wound-healing effects at that time.
Evidence strength: Anti-inflammatory data are from animal and in vitro studies only. No human clinical evidence exists for these specific endpoints.
5.7 Wound Healing
Medicinal mushroom and plant-based extracts have been verified for wound-healing properties through mechanisms targeting epithelial and dermal cell stimulation, reduction of reactive oxygen species (ROS), and modulation of inflammatory intermediates; the efficiency of the wound-healing process is largely dependent upon the balance of pro-inflammatory and pro-regenerative signals mediated by cytokines. Research at the PMC level has investigated AAP polysaccharide preparations in preclinical wound models, with results suggesting antioxidant-mediated effects on the wound microenvironment. Evidence remains preclinical.
5.8 Antiepileptic Activity (Auricularia polytricha)
A. polytricha is a mushroom used traditionally for treating asthma, rheumatism, tumors, cough, fever, and epilepsy; one study investigated its antiepileptic effect in animal models, where maximal electroshock (MES) and isoniazid (INH)-induced seizures in albino mice were used to screen for extract activity.
Per OECD Guideline 423, up to 2000 mg/kg body weight of extract was toxic in those models; animals were treated with aqueous extract at doses of 200, 400, and 600 mg/kg body weight, with phenytoin as a reference anticonvulsant drug, and a significant interruption in INH-induced clonic seizure was found.
Evidence strength: Preliminary animal data only. No human clinical trials exist for neurological endpoints.
5.9 Gut Health and Microbiome
As a major nutraceutical component, Auricularia auricula-judae polysaccharide (AAP) has been well-documented for its hypolipidemic and hypoglycemic bioactivities. One study investigated the effects of AAP on hypercaloric diet-induced cognitive dysfunction in mice; behavioral and histological results demonstrated that AAP could ameliorate high-fat and high-fructose diet-induced memory impairment and neuronal loss.
AAP significantly inhibited inflammatory responses and balanced oxidative stress in brain and colon tissues, while dietary supplements of AAP remarkably reshaped gut bacterial composition.
Dietary fiber is the major polysaccharide component of A. auricula-judae, and AAP polysaccharides have been shown to have effects on antioxidant, hypoglycemic, hypolipidemic, and immunomodulatory endpoints in various studies.
Evidence strength: Gut microbiome data are entirely from animal studies. Human gut microbiome evidence from the prospective Korean trial showed no statistically significant differences in gut environmental parameters between the intervention and control groups, reflecting the difficulty of translating animal findings to clinical outcomes.
6. Body Systems and Health Areas Associated with Auricularia
- Cardiovascular system — anticoagulant/antiplatelet activity; lipid and cholesterol modulation; antithrombotic research.
- Metabolic/endocrine system — blood glucose regulation; lipid metabolism; potential anti-obesity effects in animal models.
- Immune system — immunomodulation via macrophage activation and cytokine modulation in preclinical models.
- Gastrointestinal system — prebiotic and dietary fiber effects; gut microbiota modulation in animal models.
- Respiratory system — traditional use for lung nourishment and dry cough; preclinical anti-inflammatory data in acute lung injury models.
- Oncology (preclinical only) — in vitro and animal antitumor activity.
- Skin and wound healing — preclinical evidence for wound-healing and anti-inflammatory effects at the topical/local level.
- Central nervous system (preclinical only) — animal data on antiepileptic activity (A. polytricha) and dietary-induced cognitive decline mitigation.
7. Dosage Forms and Dosages Reported in Studies
The following dosages are reported as used in the cited source studies; they are not clinical recommendations.
- Ethanol extract (animal, oral): 150 mg/kg/d body weight of ethanol extract (AAE) administered orally to ICR mice for 8 weeks in a cholesterol-enriched diet model.
- Purified polysaccharide (animal, oral): AAP-M at 200 mg/kg/d displayed the best improvement effect in a type 2 diabetes mouse model.
- Aqueous extract (animal, oral — antiepileptic): Doses of 200, 400, and 600 mg/kg body weight were tested in albino mice in seizure induction models.
- Functional food powder (human trial, oral): The intervention group consumed functional foods containing A. auricula-judae powder twice daily for 8 weeks in a Korean prospective randomized trial, though the absolute dose of the powder per serving was not detailed in the available abstract data.
- Polysaccharide anticoagulant activity (in vitro characterization): Specific anticoagulant activity of the purified polysaccharide was 2 IU/mg, with an average molecular mass of approximately 160 kDa.
Despite being among the most cultivated edible fungi in the world, systematic research into the food and medicinal dosing parameters of Auricularia auricula remains relatively limited. No standardized human clinical dosage has been established in authoritative pharmacopoeial or regulatory monographs identified in the available literature.
8. Safety Considerations and Interactions
8.1 General Safety Profile
The polysaccharide with anticoagulant activity was isolated from "the nontoxic mushroom Auricularia auricula," as characterized in the title of the key 2003 Thrombosis Research study.
Auricularia species are generally recognized as safe food fungi with a long history of human consumption; scientific research on medicinal applications is still in the beginning stages, and the mushroom has been noted for its potential immune-enhancing and antimicrobial properties, with human research acknowledged as limited.
8.2 Anticoagulant and Antiplatelet Drug Interaction Risk
The most pharmacologically significant safety concern specific to Auricularia relates to its demonstrated anticoagulant and antiplatelet polysaccharide activity.
In ex vivo tests using rats orally fed with the polysaccharide, an inhibitory effect on platelet aggregation comparable to aspirin was observed; the polysaccharides from these mushrooms may constitute a source of compounds with action on coagulation, platelet aggregation, and thrombosis.
This mechanism implies a theoretically additive or synergistic risk when Auricularia preparations are combined with anticoagulant drugs (e.g., warfarin) or antiplatelet agents (e.g., aspirin, clopidogrel). Warfarin is susceptible to various exogenous factors including concomitant drugs and has the potential to interact with many drugs, medicinal plants, and food, which makes close monitoring necessary. Although no published human case reports of Auricularia–warfarin interaction have been identified, the established pharmacological mechanism warrants caution in individuals receiving anticoagulant or antiplatelet therapy.
8.3 Hypoglycemic Drug Interaction Risk
Given the demonstrated hypoglycemic activity of AAP in animal models, a theoretical additive interaction with antidiabetic medications (insulin, metformin, sulfonylureas) cannot be excluded. In animal models, fasting blood glucose levels and oral glucose tolerance improved significantly after AAP intervention, suggesting a pharmacodynamic basis for this concern. No human case reports or clinical studies quantifying this interaction have been identified.
8.4 Dietary Fiber-Related Gastrointestinal Effects
Auricularia is a rich source of dietary fiber, with most of its carbohydrates being indigestible polysaccharides such as β-glucans and mannans. High-fiber intake can cause gastrointestinal discomfort (bloating, flatulence, loose stools) in susceptible individuals, particularly when consumption is significantly increased.
8.5 Toxicological Data
In antiepileptic studies of Auricularia polytricha, aqueous extract at doses up to 2000 mg/kg body weight was found to be toxic in rodent models per OECD Guideline 423. These are very high acute preclinical doses and are not directly translatable to human supplement use, but they define a toxicological upper boundary in rodent models.
8.6 Overall Evidence Gap on Safety
Evaluation of Auricularia auricula polysaccharide as a novel alternative agent in thrombosis therapy requires further studies on characterization of its anticoagulant nature.
There appears to be a great disparity between the bold claims made in the literature and available evidence of use, an observation that equally extends to formal long-term safety data in human populations. No authoritative pharmacopoeial monograph (European Pharmacopoeia, USP, WHO) for Auricularia as a medicinal agent was identified in available literature, and the species is not currently the subject of a Cochrane systematic review specific to safety endpoints.
References
Go back